Delving into the Latest Updates on Suzhou SmartNuclide Biopharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Other Diseases

Diagnostic radiopharmaceuticals

Therapeutic radiopharmaceuticals

Radiolabeled antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	14
Endocrinology and Metabolic Disease	3

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	6
Therapeutic radiopharmaceuticals	5
Radionuclide Drug Conjugates (RDC)	3
Radiolabeled antibody	3
Nanobody	2

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	2
CD8A(CD8a molecule)	1
PDL1(Programmed death-ligand 1)	1
TSHR(Thyroid stimulating hormone receptor)	1
CD8(Cluster of differentiation 8)	1

主要目的考察[68Ga]Ga-NOTA-SNA002在实体瘤患者中的安全耐受性特征；考察[68Ga]Ga-NOTA-SNA002在实体瘤患者体内的生物分布特征；次要目的考察[68Ga]Ga-NOTA-SNA002在实体瘤患者中的辐射剂量学；考察[68Ga]Ga-NOTA-SNA002在实体瘤患者中血液的辐射剂量；考察[68Ga]Ga-NOTA-SNA002在实体瘤患者的PET影像特征；考察[68Ga]Ga-NOTA-SNA002的最优给药剂量；考察[68Ga]Ga-NOTA-SNA002的最优成像时间窗。探索目的探索[68Ga]Ga-NOTA-SNA002靶病灶PET影像特征（SUVmax、SUVmean、T/B比值等）与免疫组化结果PD-L1表达量的相关性；探索[68Ga]Ga-NOTA-SNA002的阳性预测和阴性预测效能。

[Translation]

Main purpose To investigate the safety and tolerability characteristics of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors; To investigate the biodistribution characteristics of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors; Secondary purpose To investigate the radiation dosimetry of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors; To investigate the radiation dose of [68Ga]Ga-NOTA-SNA002 in the blood of patients with solid tumors; To investigate the PET imaging characteristics of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors; To investigate the optimal administration dose of [68Ga]Ga-NOTA-SNA002; To investigate the optimal imaging time window of [68Ga]Ga-NOTA-SNA002. Purpose of the study To explore the correlation between the PET imaging characteristics of the target lesions of [68Ga]Ga-NOTA-SNA002 (SUVmax, SUVmean, T/B ratio, etc.) and the expression of PD-L1 in immunohistochemical results; To explore the positive and negative predictive efficacy of [68Ga]Ga-NOTA-SNA002.

Start Date01 Nov 2023

Sponsor / Collaborator

Suzhou SmartNuclide Biopharmaceutical Co., Ltd.Startup

100 Clinical Results associated with Suzhou SmartNuclide Biopharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou SmartNuclide Biopharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Suzhou SmartNuclide Biopharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou SmartNuclide Biopharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

6

Preclinical

IND Application

1

4

Phase 1 Clinical

Approved

1

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human thyroid stimulating hormone(SmartNuclide) ( TSHR )	Differentiated Thyroid Gland Carcinoma More	Approved
68Ga-SNA014	Pancreatic Cancer More	Phase 1 Clinical
SNA-014	stomach adenocarcinoma More	Phase 1 Clinical
[68Ga] anti-PD-L1 nanobody(Suzhou SmartNuclide Biopharmaceutical) ( PDL1 )	Solid tumor More	Phase 1
SNA018 ( HER2 )	Stomach Cancer More	Phase 1